Latest news with #Elahere
Yahoo
09-05-2025
- Business
- Yahoo
AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls' thesis on ABBV. AbbVie Inc. (ABBV)'s share was trading at $198.47 as of May 2nd. ABBV's trailing and forward P/E were 84.82 and 16.34 respectively according to Yahoo Finance. A clinical researcher in a lab examining a new biopharmaceutical product. AbbVie (ABBV) delivered a strong Q1 2025 performance that exceeded expectations and was met with a sharp rise in its stock price, driven by upgraded guidance and confidence in its long-term growth outlook. The company's immunology segment showed robust momentum, with Skyrizi and Rinvoq more than compensating for the anticipated decline in Humira sales. Neuroscience and oncology segments also impressed, led by Elahere, which generated $179 million in global revenue. A key catalyst was the successful conclusion of the MIRASOL trial, where Elahere significantly outperformed chemotherapy in ovarian cancer, reducing the risk of death by 32% and progression or death by 37%. This breakthrough strengthens Elahere's potential as a new standard of care and paves the way for label expansion. AbbVie continues to reinforce its position as a serial acquirer, highlighted by its acquisition of ImmunoGen for Elahere, Nimble Therapeutics for autoimmune therapies, and a recent licensing deal with Gubra targeting obesity—a high-stakes market dominated by Eli Lilly and Novo Nordisk. With Q1 revenue up 8.4% YoY (9.8% operationally), ABBV has demonstrated strong execution across its pipeline and commercial portfolio. Sustained performance at this level may warrant an upward revision of the current $215 fair value estimate. AbbVie Inc. (ABBV) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 85 hedge fund portfolios held ABBV at the end of the fourth quarter which was 68 in the previous quarter. While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
31-03-2025
- Business
- Reuters
Corcept's ovarian cancer drug cuts disease progression in study, shares jump
March 31 (Reuters) - Corcept Therapeutics (CORT.O), opens new tab said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. Shares of Corcept surged about 84% to a record high of $100.29, on track to add about $4.82 billion to the company's market capitalization, if gains hold. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. The drug, relacorilant, in combination with chemotherapy, reduced the risk of cancer progression by 30% in ovarian cancer patients who were resistant to platinum-based chemotherapy treatments, compared with those on chemotherapy alone, meeting one of the main goals of the study, Corcept said. In the trial that enrolled 381 patients, those who received the drug combination lived one month longer without their disease worsening, compared with those who received chemotherapy alone. The drug combination also showed significant improvement in overall survival, the second main goal, with patients on the treatment living for an average of 16 months, compared with 11.5 months for those on chemotherapy alone. Overall survival indicates the period of time patients lived after their diagnosis or the start of the treatment. The drug was well-tolerated with no new safety concerns, Corcept said, adding that it planned to present full study results in the coming months and file a marketing application in the U.S. in the third quarter of this year. The success of the trial will significantly build on Corcept's cortisol-modulating platform and commercial success, if approved, Canaccord Genuity analyst Edward Nash said. Nash estimates peak sales of $1.3 billion for relacorilant in platinum-resistant ovarian cancer by 2036. Relacorilant, an oral therapy, works by blocking cortisol, a stress hormone, which helps tumors resist chemotherapy, according to the company. Current treatment options for platinum-resistant ovarian cancer include AbbVie's (ABBV.N), opens new tab Elahere and Roche's (ROG.S), opens new tab Avastin. Ovarian cancer affects an estimated 238,484 women in the U.S. each year, and about 20,000 of these cases annually are classified as platinum-resistant, according to the National Cancer Institute
Yahoo
17-03-2025
- Business
- Yahoo
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate (ADC) Elahere against chemotherapy for treating platinum-resistant ovarian cancer (PROC). The randomised trial assessed the therapy's safety and efficacy when given to women with folate receptor alpha (FRα) positive PROC. Its primary endpoint was progression-free survival (PFS), with its secondary endpoints being objective response rate (ORR) and overall survival (OS). The study enrolled 453 subjects who had received up to three previous therapies and exhibited high-grade serous epithelial PROC expressing high FRα levels. The median follow-up of 30.5 months showed that ADC treatment led to a median PFS of 5.59 months compared to 3.98 months for investigator's choice (IC) chemotherapy, decreasing the tumour progression or mortality risk by 37%. In addition, it achieved an ORR of 41.9%, significantly higher than the 15.9% achieved with chemotherapy. Subjects treated with Elahere also experienced a superior median OS of 16.85 months against 13.34 months for those receiving IC chemotherapy, marking a 32% decrease in mortality risk. The drug's safety profile and duration of response were consistent with the primary data analysis at a median follow-up of 13.1 months. AbbVie oncology medical affairs vice-president Svetlana Kobina said: "Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. 'The data presented today reinforce the importance of Elahere as a transformative therapy for patients with limited options.' Elahere received full approval from the US Food and Drug Administration in March 2024 and from the European Commission last November. Several other nations are currently reviewing applications for marketing authorisation submitted by AbbVie for the drug. Last June, AbbVie released positive topline data from the Phase II PICCOLO trial, which investigated Elahere as a single agent in heavily pre-treated platinum-sensitive ovarian cancer subjects. "AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
